SG11201909325RA - 2-amino-quinoline derivatives - Google Patents
2-amino-quinoline derivativesInfo
- Publication number
- SG11201909325RA SG11201909325RA SG11201909325RA SG11201909325RA SG 11201909325R A SG11201909325R A SG 11201909325RA SG 11201909325R A SG11201909325R A SG 11201909325RA SG 11201909325R A SG11201909325R A SG 11201909325RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- beijing
- amino
- pct
- road
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, CO7D 487/04 (2006.01) A61P 29/00 (2006.01) KM, ML, MR, NE, SN, TD, TG). CO7D 471/04 (2006.01) A61P 19/00 (2006.01) A61K 31/519 (2006.01) Published: (21) International Application Number: — with international search report (Art. 21(3)) PCT/CN2018/084674 (22) International Filing Date: 26 April 2018 (26.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201710287322.2 27 April 2017 (27.04.2017) CN (71) Applicant: BIRDIE BIOPHARMACEUTICALS, INC. [GB/GB]; Sertus Chambers, P.O. Box 2547, Cassia Court, Camana Bay, Grand Cayman (KY). (71) Applicant (for BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG only): ZENG, Zhao- hui [CN/CN]; 6-5-302, #5 Hepingli Dongcheng, Beijing 100013 (CN). (72) Inventors: LI, Lixin; 1 Xiushui Road Chaoyang, Bei- jing 100600 (CN). GUAN, Huiping; 1 Xiushui Road, Chaoyang, Beijing 100600 (CN). (74) Agent: BEIJING KINSCOM INTELLECTUAL PROP- ERTY CO., LTD.; Room 802, Tower B, Global Trade Center, No. 36 Beisanhuan East Road, Dongcheng, Beijing 100013 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: 2-AMINO-QUINOLINE DERIVATIVES (57) : Described herein are 2-amino-quinoline derivatives that are agonists of toll-like receptors 7 and 8 (TLR7/8), pharma- ceutical compositions, and methods of use of the compounds and compositions to treat various diseases, such as viral, cancer, and allergic diseases, in need thereof by administering a therapeutically effective amount of a 2-amino-quinoline derivative. omit IIl °nolo oimIE (10) International Publication Number WO 2018/196823 Al W O 20 18/1968 23 Al
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710287322.2A CN108794467A (en) | 2017-04-27 | 2017-04-27 | 2- amino-quinoline derivatives |
PCT/CN2018/084674 WO2018196823A1 (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909325RA true SG11201909325RA (en) | 2019-11-28 |
Family
ID=63918846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909325R SG11201909325RA (en) | 2017-04-27 | 2018-04-26 | 2-amino-quinoline derivatives |
Country Status (13)
Country | Link |
---|---|
US (3) | US11053240B2 (en) |
EP (1) | EP3615539B1 (en) |
JP (1) | JP7179357B2 (en) |
KR (1) | KR102541238B1 (en) |
CN (2) | CN108794467A (en) |
AU (1) | AU2018259831B2 (en) |
BR (1) | BR112019022246A2 (en) |
CA (1) | CA3061187A1 (en) |
IL (1) | IL270219B (en) |
MX (1) | MX2019012676A (en) |
RU (1) | RU2019138177A (en) |
SG (1) | SG11201909325RA (en) |
WO (1) | WO2018196823A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112587671A (en) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | Targeted immunotherapy for cancer |
EP3092255A4 (en) | 2014-01-10 | 2017-09-20 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for treating egfr expressing tumors |
JP6760919B2 (en) | 2014-07-09 | 2020-09-23 | バーディー バイオファーマシューティカルズ インコーポレイテッド | Anti-PD-L1 combination for treating tumors |
CN112587672A (en) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | anti-PD-L1 conjugates for the treatment of tumors |
CN106943596A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti-CD 20 for treating tumour is combined |
CN106943597A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti-EGFR for treating tumour is combined |
CN106943598A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti- HER2 for treating tumour is combined |
WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
CN108794467A (en) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2- amino-quinoline derivatives |
WO2018232725A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
BR112021015577A8 (en) | 2019-02-08 | 2021-10-05 | Research & Business Found Sungkyunkwan Univ | Toll-like receptor 7/8 agonist cholesterol-complex, nanoparticle composition, adjuvant composition, vaccine composition, composition for regulating immune function, pharmaceutical composition and use of the complex |
WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
US11530218B2 (en) | 2020-01-20 | 2022-12-20 | Incyte Corporation | Spiro compounds as inhibitors of KRAS |
US20230100429A1 (en) | 2020-03-02 | 2023-03-30 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
US20230277525A1 (en) | 2020-08-04 | 2023-09-07 | Progeneer Inc | Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof |
JP2023536953A (en) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | mRNA Vaccines Containing Dynamically Controllable Adjuvants |
JP2023536945A (en) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | Kinetic Adjuvant Ensemble |
WO2022047093A1 (en) | 2020-08-28 | 2022-03-03 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of kras |
WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
EP4294805A1 (en) * | 2021-02-22 | 2023-12-27 | Regents of the University of Minnesota | Immunomodulators and immunomodulator conjugates |
IL312114A (en) | 2021-10-14 | 2024-06-01 | Incyte Corp | Quinoline compounds as inhibitors of kras |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US6608201B2 (en) | 1992-08-28 | 2003-08-19 | 3M Innovative Properties Company | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
UA67760C2 (en) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
EP2283867B1 (en) | 1999-06-25 | 2014-05-21 | ImmunoGen, Inc. | Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US20060142202A1 (en) | 2000-12-08 | 2006-06-29 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
JP2005519990A (en) | 2001-10-12 | 2005-07-07 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Methods and products for enhancing immune responses using imidazoquinoline compounds |
ATE416771T1 (en) | 2001-11-16 | 2008-12-15 | 3M Innovative Properties Co | N-Ä4-(4-AMINO-2-ETHYL-1H-IMIDAZOÄ4,5-CUCHINOLINE 1-YL)BUTYLUMETHANESULFONAMIDE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF |
ATE448238T1 (en) | 2001-11-27 | 2009-11-15 | Anadys Pharmaceuticals Inc | 3-BETA-D-RIBOFURANOSYLTHIAZOLO(4,5-DELTA)PYRIDIMININE NUCLEOSIDES AND THEIR USE |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
ES2654064T3 (en) | 2002-07-03 | 2024-03-13 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
EP1413316A1 (en) | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
WO2004058759A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
EP1576014B1 (en) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Antibodies against pd-1 and uses thereof |
CA2512672A1 (en) | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Methods of treating lung diseases |
US9259459B2 (en) | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | Methods and compositions related to irm compounds and toll-like receptor 8 |
KR20060096415A (en) | 2003-09-05 | 2006-09-11 | 애나디스 파마슈티칼스, 인코포레이티드 | Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus |
AU2004278014B2 (en) * | 2003-10-03 | 2011-04-28 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
KR101494056B1 (en) | 2003-10-03 | 2015-02-16 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Pyrazolopyridines and analogs thereof |
RU2426734C2 (en) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Pyrazolopyridines and analogues thereof |
CA2542099A1 (en) | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
EP1699398A4 (en) | 2003-12-30 | 2007-10-17 | 3M Innovative Properties Co | Enhancement of immune responses |
AU2005226359B2 (en) | 2004-03-26 | 2011-02-03 | Astrazeneca Aktiebolag | 9-substituted 8-oxoadenine compound |
EP1776105A2 (en) | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
WO2006052900A2 (en) | 2004-11-09 | 2006-05-18 | University Of Southern California | Targeted innate immunity |
JP2008526765A (en) | 2004-12-30 | 2008-07-24 | スリーエム イノベイティブ プロパティズ カンパニー | Treatment of skin metastases |
AU2006216629A1 (en) | 2005-02-24 | 2006-08-31 | Janssen Pharmaceutica N.V. | Novel quinoline derivatives as potassium ion channel openers |
AU2006233675A1 (en) | 2005-04-14 | 2006-10-19 | Merck Patent Gmbh | Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues |
ES2477765T3 (en) | 2005-04-19 | 2014-07-17 | Seattle Genetics, Inc. | Binding agents to humanized anti-cd70 and their uses |
KR101205064B1 (en) | 2005-04-26 | 2012-11-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Compositions and methods for cancer immunotherapy |
KR101339628B1 (en) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
KR101888321B1 (en) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | Human monoclonal antibodies to programmed death ligand 1(pd-l1) |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
TW201402124A (en) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 8-substituted benzoazepines as toll-like receptor modulators |
TWI382019B (en) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | Aminodiazepines as toll-like receptor modulators |
JP2009506790A (en) | 2005-09-07 | 2009-02-19 | メディミューン,エルエルシー | EPH receptor antibody conjugated to toxin |
ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
EP3085373A1 (en) | 2006-02-22 | 2016-10-26 | 3M Innovative Properties Company | Immune response modifier conjugates |
WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
WO2008004948A1 (en) | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
ES2636089T3 (en) | 2006-10-27 | 2017-10-05 | Genentech, Inc. | Antibodies and immunoconjugates and uses for them |
CA2673444C (en) | 2006-12-21 | 2015-01-20 | F. Hoffmann-La Roche Ag | Polymorphs of a mglur5 receptor antagonist |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
TWI422594B (en) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr) |
PL2510946T3 (en) | 2007-02-07 | 2015-12-31 | Univ California | Conjugates of synthetic tlr agonists and uses therefor |
PL2155743T3 (en) | 2007-05-08 | 2013-01-31 | Astrazeneca Ab | Imidazoquinolines with immuno-modulating properties |
CA2695385A1 (en) | 2007-07-31 | 2009-02-05 | Atul Bedi | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
GB0715428D0 (en) * | 2007-08-08 | 2007-09-19 | Imp Innovations Ltd | Compositions and uses thereof |
ES2647538T3 (en) | 2007-09-28 | 2017-12-22 | Pfizer Inc. | Addressing to cancer cells using nanoparticles |
MX2010007699A (en) | 2008-01-15 | 2010-08-04 | Meda Ab | Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives. |
CA2713137C (en) | 2008-01-25 | 2017-10-24 | Hadasit Medical Research Services And Development Ltd. | Targeting of innate immune response to tumor site |
US20090202626A1 (en) | 2008-02-07 | 2009-08-13 | Carson Dennis A | Treatment of bladder diseases with a tlr7 activator |
AR070865A1 (en) | 2008-03-18 | 2010-05-12 | Genentech Inc | COMBINATIONS OF AN ANTIBODY-ANTI-HER2 PHARMACO AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE |
EP2316032A1 (en) | 2008-08-20 | 2011-05-04 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8 |
WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
PT2364314E (en) | 2008-12-09 | 2014-06-09 | Gilead Sciences Inc | Modulators of toll-like receptors |
PT2427485T (en) | 2009-05-07 | 2017-03-13 | Immunocellular Therapeutics Ltd | Cd133 epitopes |
WO2010132622A2 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California | Anticd20-cpg conjugates and methods of treating b cell malignancies |
US20110077263A1 (en) | 2009-09-29 | 2011-03-31 | University Of Southern California | Methods and Compositions of Toll-Like Receptor (TLR) Agonists |
WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
WO2011084725A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
WO2011084726A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
KR101958753B1 (en) | 2010-04-13 | 2019-03-15 | 셀덱스 쎄라퓨틱스, 인크. | Antibodies that bind human cd27 and uses thereof |
MX2012013713A (en) | 2010-05-26 | 2013-01-28 | Selecta Biosciences Inc | Nanocarrier compositions with uncoupled adjuvant. |
TWI506035B (en) | 2010-08-13 | 2015-11-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
SG189071A1 (en) | 2010-10-01 | 2013-05-31 | Ventirx Pharmaceuticals Inc | Therapeutic use of a tlr agonist and combination therapy |
JP2014502596A (en) | 2010-12-09 | 2014-02-03 | ジェネンテック, インコーポレイテッド | Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1 |
WO2012097177A2 (en) | 2011-01-12 | 2012-07-19 | Ventirx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
CA2826186C (en) | 2011-02-01 | 2020-08-04 | Genmab A/S | Human antibodies and antibody-drug conjugates against cd74 |
US20120231023A1 (en) | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells |
WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
UY34032A (en) * | 2011-04-21 | 2012-11-30 | Origenis Gmbh | NEW QUINASA INHIBITORS |
WO2012143143A1 (en) * | 2011-04-21 | 2012-10-26 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
EP2734551B1 (en) | 2011-07-24 | 2018-01-10 | Cure Tech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
PE20141693A1 (en) | 2011-08-01 | 2014-11-24 | Genentech Inc | METHODS TO TREAT CANCER BY THE USE OF AXIS BINDING ANTAGONISTS PD-1 AND MEK INHIBITORS |
KR101899801B1 (en) | 2011-08-11 | 2018-09-20 | 헌츠만 어드밴스드 머티리얼스 아메리카스 엘엘씨 | Method for producing benzoxazine compounds |
JP2014527983A (en) | 2011-09-19 | 2014-10-23 | ザ ジョンズ ホプキンス ユニバーシティー | Cancer immunotherapy |
EP2771301B1 (en) | 2011-10-25 | 2017-12-20 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
WO2013067597A1 (en) | 2011-11-09 | 2013-05-16 | Ascend Biopharmaceuticals Pty Ltd | Immunomodulatory conjugates |
US9556167B2 (en) | 2012-05-02 | 2017-01-31 | Yale University | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) |
CN104470949A (en) | 2012-05-15 | 2015-03-25 | 百时美施贵宝公司 | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
CN112587671A (en) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | Targeted immunotherapy for cancer |
EP2890715B1 (en) | 2012-08-03 | 2020-12-16 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
KR102355959B1 (en) | 2012-08-23 | 2022-01-27 | 어젠시스 인코포레이티드 | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
WO2014060112A1 (en) * | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
US10000482B2 (en) * | 2012-10-19 | 2018-06-19 | Origenis Gmbh | Kinase inhibitors |
EP2787005A1 (en) | 2013-04-02 | 2014-10-08 | Activartis Biotech GmbH | Targeted cancer immune therapy |
NZ721908A (en) | 2013-12-20 | 2022-12-23 | Massachusetts Gen Hospital | Combination therapy with neoantigen vaccine |
EP3092255A4 (en) | 2014-01-10 | 2017-09-20 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for treating egfr expressing tumors |
WO2015200728A1 (en) | 2014-06-25 | 2015-12-30 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
CN112546230A (en) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | Combination therapeutic compositions and combination therapeutic methods for treating cancer |
JP6760919B2 (en) | 2014-07-09 | 2020-09-23 | バーディー バイオファーマシューティカルズ インコーポレイテッド | Anti-PD-L1 combination for treating tumors |
CN112587672A (en) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | anti-PD-L1 conjugates for the treatment of tumors |
CN105732635A (en) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | Toll-like receptor 7 agonist |
RU2705579C2 (en) | 2015-09-01 | 2019-11-08 | Тайхо Фармасьютикал Ко., Лтд. | Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof |
US10821127B2 (en) | 2015-11-09 | 2020-11-03 | Shaperon Inc. | Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient |
CN106943598A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti- HER2 for treating tumour is combined |
CN106943597A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti-EGFR for treating tumour is combined |
CN106943596A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti-CD 20 for treating tumour is combined |
CN108794467A (en) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2- amino-quinoline derivatives |
WO2018232725A1 (en) | 2017-06-23 | 2018-12-27 | Birdie Biopharmaceuticals, Inc. | Pharmaceutical compositions |
AU2019335366A1 (en) | 2018-09-07 | 2021-03-25 | Birdie Biopharmaceuticals, Inc. | Imidazoquinoline compounds and uses thereof |
JP2022516093A (en) | 2018-12-26 | 2022-02-24 | バーディー バイオファーマシューティカルズ インコーポレイテッド | Combinations and methods of immunomodulators for the treatment of cancer |
US20220175762A1 (en) | 2019-03-15 | 2022-06-09 | Birdie Biopharmaceuticals, Inc. | Immune modulatory compositions and methods for treating cancers |
KR20230057409A (en) | 2020-08-26 | 2023-04-28 | 버디 바이오파마슈티칼즈, 인크. | Cancer treatment using TLR agonists |
-
2017
- 2017-04-27 CN CN201710287322.2A patent/CN108794467A/en active Pending
-
2018
- 2018-04-26 US US16/608,581 patent/US11053240B2/en active Active
- 2018-04-26 JP JP2019558496A patent/JP7179357B2/en active Active
- 2018-04-26 AU AU2018259831A patent/AU2018259831B2/en active Active
- 2018-04-26 SG SG11201909325R patent/SG11201909325RA/en unknown
- 2018-04-26 WO PCT/CN2018/084674 patent/WO2018196823A1/en unknown
- 2018-04-26 EP EP18792253.9A patent/EP3615539B1/en active Active
- 2018-04-26 IL IL270219A patent/IL270219B/en unknown
- 2018-04-26 CN CN201880014574.0A patent/CN110637018A/en active Pending
- 2018-04-26 MX MX2019012676A patent/MX2019012676A/en unknown
- 2018-04-26 CA CA3061187A patent/CA3061187A1/en active Pending
- 2018-04-26 KR KR1020197033158A patent/KR102541238B1/en active IP Right Grant
- 2018-04-26 BR BR112019022246-4A patent/BR112019022246A2/en unknown
- 2018-04-26 RU RU2019138177A patent/RU2019138177A/en not_active Application Discontinuation
-
2021
- 2021-05-07 US US17/315,162 patent/US20210261549A1/en not_active Abandoned
- 2021-05-07 US US17/315,156 patent/US11834448B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20190141174A (en) | 2019-12-23 |
US20210261549A1 (en) | 2021-08-26 |
EP3615539A1 (en) | 2020-03-04 |
RU2019138177A (en) | 2021-05-27 |
US11834448B2 (en) | 2023-12-05 |
CN108794467A (en) | 2018-11-13 |
EP3615539B1 (en) | 2023-08-09 |
MX2019012676A (en) | 2020-02-05 |
RU2019138177A3 (en) | 2021-05-27 |
KR102541238B1 (en) | 2023-06-08 |
IL270219A (en) | 2019-12-31 |
AU2018259831B2 (en) | 2022-06-16 |
JP7179357B2 (en) | 2022-11-29 |
BR112019022246A2 (en) | 2020-08-11 |
US11053240B2 (en) | 2021-07-06 |
EP3615539A4 (en) | 2020-08-19 |
IL270219B (en) | 2022-09-01 |
CN110637018A (en) | 2019-12-31 |
WO2018196823A1 (en) | 2018-11-01 |
US20210261548A1 (en) | 2021-08-26 |
CA3061187A1 (en) | 2018-11-01 |
AU2018259831A1 (en) | 2019-10-31 |
US20200055851A1 (en) | 2020-02-20 |
JP2020517711A (en) | 2020-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909325RA (en) | 2-amino-quinoline derivatives | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
SG11201900596XA (en) | Cannabis composition | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
SG11201804811WA (en) | Fenfluramine compositions and methods of preparing the same | |
SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901576QA (en) | Dosage regimen for a controlled-release pth compound | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis | |
SG11201909552VA (en) | Combination therapy for prostate cancer |